Abstract
INTRODUCTION

Rationale
The multidisciplinary treatment of rectal cancer has markedly improved and led to better patient outcomes over the last three decades [1] . The reasons for this are multifactorial, but one important factor is the use of neo-adjuvant or adjuvant therapies [2] . The degree of primary tumour regression following neo-adjuvant therapy, identified on final histopathological specimens, has been shown to be a prognostic factor [3, 4] . The variation in response allows clinicians to riskstratify patients after surgery, which may help in postoperative decisions, such as who to treat with adjuvant chemotherapy and the intensity of follow-up.
Clinical studies use a number of different tumour regression grade (pTRG) scales to classify the degree of tumour response to neo-adjuvant chemo-radiotherapy (CRT). This often results in confusion as to whether a good or poor response has been achieved, with subsequent uncertainty regarding treatment and prognostic implications. This problem was highlighted by MacGregor et al [1] who stressed the importance of a universally accepted standard. There has been no review of the reported pTRG scales to date. It is necessary to highlight the heterogeneity in these scales, in order to consolidate the current definitions with the purpose of converging towards a set of consensus definitions.
A newer method of assessing tumour regression relies on MRI (mrTRG), which has been validated as a prognostic tool. This may supercede pTRG, as it has the advantage of assessing tumour response before surgery. As such, it has the potential for enabling response-orientated tailored treatment, including alteration of the surgical planes, additional use of chemotherapy, or deferral of surgery [5] [6] [7] .
Objective
This article investigates all the pathology tumour regression scales used to define good and poor response after neo-adjuvant chemotherapy for rectal cancer, to establish the true prevalence of poor responders and to identify the best scales to use in relation to outcomes.
MATERIALS AND METHODS
Protocol and registration
The title, methods and outcome measures were stipulated in advance and the protocol is available in the PROSPERO database [8] .
Types of studies
All clinical, histopathological and imaging studies that define or attempt to define good and poor responders after neo-adjuvant therapy for colorectal cancers were identified. Included studies were those investigating rectal cancer response to neo-adjuvant therapy incorporating chemotherapy, radiotherapy or chemoradiotherapy with different protocols. All clinical studies were chosen that defined good and poor response in relation to TRG or degree of response according to histopathology using terms such as "poor response", "minor response", "less response", "good response", "major response" or "more response".
Types of participants
All rectal cancer patients treated with long course radiotherapy or an interval period to surgery were selected for this review. All sensitizing chemotherapy protocols were included. Any surgical resection was included. Studies were also included with any postoperative adjuvant practice.
Exclusion criteria
Excluded studies were those that did not specifically state whether a response was good or poor, or that qualify it with some form of inference in the paper. Further exclusions were for: non-conventional deliveries of neo-adjuvant therapy, such as endo-rectal brachytherapy; trans-anal endoscopic microsurgery (commonly known as TEMS) and local excisions; and, when the reporting scale was in obvious contradiction with the order given in the original studies [9] .
Types of variable of interest
The original papers reporting the various pTRG scales were identified and articles that used the scales in clinical, pathological and MRI studies were used in the current study.
Hypotheses and types of outcome measures
The primary hypothesis was that there is an optimal histopathological TRG scale that appropriately distinguishes between good and poor response. The secondary hypothesis was that the mrTRG scale differentiates between good and poor response. This was investigated by first reviewing the clinical studies examining the response of rectal cancer to neoadjuvant therapy. These studies were used to show the range of definitions of good and poor response according to histopathology and MRI. This was then utilised to identify the optimal scale for identifying good and poor response after neo-adjuvant therapy for rectal cancer based on recurrence and survival outcomes.
Information sources
The Cochrane library, CENTRAL, EMBASE, CINAHL and PubMed databases were searched between January 1935 and December 2015. Relevant articles referenced in these publications were obtained and the "related article" function was used to widen the results. This was complemented by hand searches and cross-references from papers identified during the initial search. No language restriction was applied.
Searches
The text words "preoperative", "neo-adjuvant", "tumour regression", "poor responder", "good responder", "regression grading", "regression grade" and "rectal cancer" were used in combination with the medical subject headings "adjuvant combined modality therapy" and "rectal cancer". Irrelevant articles not fulfilling the inclusion criteria were excluded.
Study selection and data collection process
Each included article according to our review criteria was reviewed by two researchers (MRSS and JB). Where more specific data or missing data was required, the authors of the manuscripts were contacted. Data was entered onto an Excel worksheet and compared between authors. Any disagreements that arose between the reviewers were resolved through discussion, and if no consensus could be reached a third author (GB) would decide.
Data items
Data were extracted that related to the definition of good and poor response according to the TRG scales reported in clinical, histopathological and imaging studies. The ranges of permutations of each TRG scale to define good or poor response were also documented and the most commonly used definitions identified. The primary hypothesis was proven by examining all of the studies on response to neo-adjuvant therapy and there is a single definition (which may include other scales) that consistently differentiates between good and poor responses as defined by local recurrence (LR), distant recurrence (DR), disease-free survival (DFS) and overall survival (OS).
Risk of bias and quality assessment
Quality assessment and risk of bias was not formally assessed due to the exploratory nature of this review. Validity of other studies was benchmarked to studies that identified a significant difference. Clinical heterogeneity can be seen in the table of  characteristics presented as Table 1 .
Summary measures and data synthesis for summative and comparative meta-analyses
As part of assessing overall prevalence of poor responders, cumulative meta-analytical techniques were used. Analyses were performed using Comprehensive Meta-Analysis 2006 (Version 2, Biostat, Englewood, NJ, United States) for Windows 10 [10] . In a sensitivity analysis, 0.5 was added to each cell frequency for reported 25 definitions for poor response in accordance with the TRG . Of these, 16 articles also defined good response. Table 1 shows the characteristics of individual studies.
Qualitative and quantitative syntheses
Histopathological methods of classifying regres sion: There were 19 TRG scales reported across the studies [18, 25, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] (Table 2) . Only one TRG system incorporated whether a response was poor or good [36] and used a categorical TRG scale based on the one described by Dworak et al [35] .
Which scales are used to define poor response using histopathological methods?
From the search, nine scales [18, 25, [34] [35] [36] 38, 40, 43, 44, 46] were used in 25 reports (21 articles) to define poor response . From these 25 reports, the nine scales were used in different combinations to produce 16 individual definitions of poor response (Table 3) . trials in which no event occurred, according to the method recommended by Deeks et al [11] and was not considered to affect the overall result necessitating the Peto method [12] . Where only a single patient was present in any of the groups, this was excluded due to the excessive effect of zero cell correction. Outcomes were reported as event rates. Forest plots were used for the graphical display.
Publication bias
For the outcome of prevalence, publication bias was assessed using funnel plots. We used the plots to subjectively assess asymmetry and conducted an Egger test for quantitative assessment.
RESULTS
Study selection and characteristics
There were 328 references. Full texts of 85 papers were reviewed. Overall, 21 articles were of relevance and 
Adjuvant therapy
Gambacorta et al [21] [17] 2008 Fluorouracil 45-50 APR/AR Y T3/4, N1/2 Giralt et al [22] 2008
Tegafir uracil, leucovorin 45 + 9 boost APR/AR Y 4-6 T3/4, N0/1/2 Y Horisberger et al [24] 2008 Capecitabine, irinotecan 50.4 APR/AR/stoma Y 4-7 T2/3/4, N+ Suárez et al [31] 2008
Fluoropyridine Avallone et al [13] 2011 Fluorouracil, levofolinic acid, ralitrexed, oxaliplatin
Eich et al [19] [27] 2011 Fluorouracil, leucovorin 50.4 APR/AR Y 6 T3/4, N0/1/2 Shin et al [30] 2011 Fluorouracil 25-50.4 APR/AR/Pan 4-6 T3/4 Huebner et al [25] 2012
Fluorouracil APR/AR T1/2/3/4, N0/1/2 Y Lim et al [26] 2012
Capecitabine, fluorouracil, leucovorin 44-46+4. 6 boost
Roy et al [29] 2012 Capecitabine, fluorouracil
Vallböhmer et al [32] 2012 Fluorouracil 50.4 APR/AR Y T3/4, N0/1/2 Winkler et al [33] 2012 Capecitabine, oxaliplatin 45-50.4 Y 4-6 Stage 2 or 3 Y Elezkurtaj et al [20] 2013 Fluorouracil 50.4 Y 4-6 Hermanek et al [23] 2013 APR/AR/ Hartmann's Y Y Fokas et al [14] [15] 2015 Fluorouracil, cetuximab, oxaliplatin [35] [38] [18, 44] [25] 0 No regression 1a
Minimal effect (necrosis less than 1/3) 1b
Mild effect (necrosis less than 2/3 but more than 1/3) 2
Moderate effect (necrosis more than 2/3 of the lesion) 3 No tumour cells TRG scale Ruo (Low no. -Less regression) [39] 0 [46] The overall proportion of poor responders after neoadjuvant CRT was 37.7% (95%CI: 30.1-45.8) ( Table  4 , Figure 1 ). Study characteristics can be seen in Table 1 . Table 5 shows the scales that define poor response with their permutations. Most studies used the Mandard or Dworak TRG scales. The studies using the Mandard scale [13, 16, 21, 22, [28] [29] [30] [31] defined poor response as Mandard TRG 3 to 5, 4 or 4 to 5. The Dworak scale uses a similar numerical scale in the opposite direction to the Mandard system. From the articles that use the Dworak classification for their definitions [14] [15] [16] 20, 25, 26, 29, 33] , a poor response was defined as Dworak 0 to 1, 1, 1 to 2 or 0 to 2.
Outcomes of poor response defined by histopathological scales
Fourteen studies that defined poor response reported on outcomes (Table 5 ). LR at 5 years ranged from 2% to 26% [17, 18, 23, 26, 27, 31] , DR was 14.3% to 47% [18, 23, 26, 27, 31] . One study reported 10-year LR and DR of 3.6% and 39.6%, respectively [14] . Two-year DFS was 60.3% to 83.6% [19, 29, 31] , 3-year DFS was 72.6% to 73.8% [30, 31] , 4-year DFS was reported by a single study as 47% [18] , 5-year DFS was reported as 56% to 71% [13, 16, 17, 23, 26] , and 10-year DFS was documented as 63% [14] . OS at 2 years was 87.3% to 92.6% [29] and at 5 years was 60.7% to 75.8% [16, 23, 26] .
Which scales are used to define good response?
Six scales [18, 25, 35, 40, 43, 44, 46] were used in 20 reports (16 articles) to define good response [13] [14] [15] [16] 18, 20, 21, [24] [25] [26] [28] [29] [30] [31] [32] [33] . These six scales produced 12 different definitions of good response ( Table 2 ). The characteristics of these studies are shown in Table 1 . Table 6 shows the scales defining good response along with their permutations.
Outcomes of good response defined by pathological scales
Ten studies reported on outcomes (Table 6 ). Most studies defined good response as Mandard 1 to 2, 1 to 3, 2 to 3 or Dworak 2 to 4, 3 to 4 or 2 to 3. LR at 5 years after a good response ranged from 0% to 9% [16, 18, 26, 31] and DR was reported as 0% to 34% [16, 18, 26, 31] . One study reported 10-year LR and DR of 8.0% and 29.3%, respectively [14] . Two-year DFS was 86.1% to 91.7% [29] , 3-year DFS was 74.1% [30] , 4-year DFS was 67% [18] , 5-year DFS was 78.4% to > 90% [13, 16, 26] , and 10-year DFS was 73.6% [14] . OS at 2 years was 89.2% to 92.2% [29] , and at 5 years OS was [51] TRGN 1 Complete regression with absence of residual cancer and fibrosis extending through the wall TRGN 2
Presence of rare residual cancer cells scattered through the fibrosis TRGN 3
An increased number of residual cancer cells, but fibrosis is still predominant Suárez et al [31] Mandard TRG 1,2 Suárez et al [31] Santos et al [16] Gambacorta et al [21] Santos et al [16] Mandard TRG 4 Gambacorta et al [21] Mandard TRG 2,3 Avallone et al [13] Giralt et al [22] Mandard TRG 4,5
Avallone et al [13] Mandard TRG 1,2,3
Roy et al [29] Roy et al [29] Pucciarelli et al [28] Pucciarelli et al [28] Shin et al [30] Shin et al [30] Dworak 1 Winkler et al [33] Dworak TRG 2,3,4
Huebner et al [25] Roy et al [29] Dworak TRG 0,1 Huebner et al [25] Dworak TRG 2,3 Fokas et al [14] Roy et al [29] Fokas et al [14] Dworak TRG 1,2 Lim et al [26] Dworak TRG 3,4 Lim et al [26] Elezkurtaj et al [20] Santos et al [16] Hav et al [15] Dworak TRG 0,1,2
Elezkurtaj et al [20] Dworak TRG 3 Winkler et al [33] Hav et al [15] Santos et al [16] Rodel TRG 3
Min et al [27] Japanese TRG 2,3 Horisberger et al [24] Rodel TRG 3 [Wittekind (mod Dworak 0,1)]
Hermanek et al [23] Japanese TRG 3 Vallböhmer et al [32] Japanese TRG 0,1a,1b
Horisberger et al [24] Miller Junker TRG 2a and 2b
Vallböhmer et al [32] Japanese TRG 1 Vallböhmer et al [32] Cologne TRG 3 and 4
Vallböhmer et al [32] Miller Junker TRG 1
Vallböhmer et al [32] Glynne Jones TRG 1
Bujko et al [18] Miller Junker TRG 1,2a
Eich et al [19] Cologne TRG 1,2 Vallböhmer et al [32] Glynne Jones TRG 3
Bujko et al [18] Wheeler RCRG TRG 2
Beddy et al [17] 77.4% to 88.2% [16, 26] .
Considerations and comparison between good and poor responders
A range of survival outcomes existed for good and poor response (Table 7 ). There were 15 reports (11 articles) comparing outcomes from good and poor response [13] [14] [15] [16] 18, 26, [28] [29] [30] [31] [32] . Four outcome measures were examined in detail: LR, DR, DFS and OS.
Studies differentiating between good and poor responders for LR
Six reports from five studies [14, 16, 18, 26, 31] compared good and poor response in relation to LR (Figure 2 ). Of these, one study reported a non-significantly higher LR in good responders compared with poor responders [14] . Five reports [16, 18, 26, 31] showed LR was higher in poor responders, of which only one study showed a significant difference [26] . Using the definition given by Lim et al [26] there were three other studies with similar definitions [16, 31] . The reported LR for good response ranged from 0% to 1.8% [16, 26, 31] . There were no studies that agreed with Lim et al [26] for the definition of poor response. Three studies [16, 31] agreed with each other for poor response and reported LR of 3.4% to 4.3%. Lim et al [26] (which showed a significant difference between good and poor) gave LR rate in poor responders of 9.5%. This indicates that either Mandard 1 to 2 or Dworak 3 to 4 should be used to define good response for LR and Mandard 3 to 5 or Dworak 0 to 2 or 1 to 2 should be 
DFS (%) OS (%)
Gambacorta et al [21] 2004 Mandard (oesophagus) Yes TRG 4 54 10 25
Pucciarelli et al [28] 2004 Mandard (oesophagus) Yes TRG 4 and 5 106 52 42 Beddy et al [17] [22] 2008 Mandard (oesophagus) No TRG 4 68 7 Horisberger et al [24] 2008
Japanese Society for Cancer of the Colon and Rectum (rectal) Yes TRG 0 and 1a and 1b 59 26
Suárez et al [31] 2008 [18] 2010
Glynne Jones/Bujko (rectal) Avallone et al [13] 2011 Mandard (oesophagus) Yes TRG 4 and 5 63 9 60 Yr. 5: Prob free of recurrence 56 2 Eich et al [19] 2011 Min et al [27] 2011 Shin et al [30] 2011 [25] 2012
Dworak (rectal) Yes TRG 0+1 237 61
Lim et al [26] [32] 2012
Japanese Society for Cancer of the Colon and Rectum (rectal) Yes TRG 1 85 23
Vallböhmer et al [32] 2012 Junker Miller (lung) Yes TRG 1 85 6 DNE
Vallböhmer et al [32] 2012 Cologne (oesophageal) Yes TRG 1 and 2 85 53 DNE
Winkler et al [33] 2012 Dworak (rectal) No TRG 1 33 9 DNE Elezkurtaj et al [20] 2013
Dworak (rectal) Yes TRG 0,1 and 2 102 68
Hermanek et al [23] Overall rate for total follow-up time; 2 Probability of being free from recurrence (DFS rate not given). LR: Local recurrence; DR: Distant recurrence.
used for poor response.
Studies differentiating between good and poor response for DR
Six reports from five studies [14, 16, 18, 26, 31] compared good and poor response in relation to DR (Figure 3 ). Of these, all showed DR was higher in poor responders, of which two studies (Lim et al [26] and Fokas et al [14] ) showed a significant difference; although, they used different definitions. Using the definition given by Lim et al [26] , there were three other studies with similar definitions [16, 31] ; the reported 5-year DR for good response was 0% to 11.6%. Using the definition given by Fokas et al [14] , there was one other study with a similar definition [18] ; the reported 5-and 10-year DR for good response was 34% and 29%, respectively. Poor response was defined by three studies [16, 31] , with similar definitions reporting DR of 14.3% to 20.3%. Poor response was 47% and 39.6% for 5-and 10-year DR, respectively, by two other studies [14, 18] with similar 
DFS (%) OS (%)
Gambacorta et al [21] 2004 Mandard (oesophagus) Yes TRG 1 and 2 54 24 25
Pucciarelli et al [28] 2004
Horisberger et al [24] 2008
Suárez et al [31] 2008 [18] 2010 Glynne Jones/ Bujko (rectal) Elezkurtaj et al [20] 2013 Dworak (rectal) Yes TRG 3 and 4 102 34
Fokas et al [14] [28] 2004 TRG 1 and 2 and 3 TRG 4 and 5
Better in GR No Better in GR No
Good responders have better, non-statistically significant outcomes for DFS and OS Suárez et al [31] 2008 [26] 2012 TRG 3 and 4 [32] 2012 TRG 3 TRG 1
Better in GR No
Good responders have better, non-statistically significant outcomes for OS Vallböhmer et al [32] 2012 TRG 2a and 2b
TRG 1 Better in GR No
Good responders have better, non-statistically significant outcomes for OS Vallböhmer et al [32] 2012 TRG 3 and 4 TRG 1 and 2
Better in GR No
There was no statistically significant difference for OS between good and poor responders Fokas et al [14] 2014 TRG 2 and 3 [16] 2014 TRG 3 and 4 [15] 2015 TRG 3 and 4 definitions. Lim et al [26] reported 5-year DR as 27.2%
for poor responders. The values reported by Fokas et al [14] and Bujko et al [18] are much higher than the other reports and do not reflect the body of literature. It would, therefore, be preferable to use either Mandard 1 to 2 or Dworak 3 to 4 for defining good response for DR and Mandard 3 to 5 or Dworak 0 to 2 or 1 to 2 for poor response. 
Studies differentiating between good and poor response for DFS
Twelve reports [13] [14] [15] [16] 18, 26, [28] [29] [30] [31] compared good and poor response in relation to DFS (Figure 4) . All of the studies showed DFS to be worse in poor responders.
Six studies showed a significant difference between good and poor response [13, 14, 16, 26, 29, 31] . For the definition of good response, three of the papers [16, 26, 31] showing a statistical significance used a similar definition to each other; two [13, 14] used different definitions but were to the other significant studies [29] . Using the definition given by Lim et al [26] and comparing it to studies with similar definitions [15, 16, 30, 31] , the reported DFS for good response at 5 years was 78.4% to 86.7%. Using the definition given by Fokas et al [14] and comparing it with the other reports with similar definitions [13] , the reported 5-and 10-year DFS for good response was > 90% and 73.6%, respectively. Using the definition by Roy et al [29] and comparing it with the other studies with similar definitions [28] [29] [30] , 2-year DFS was 86.1% to 91.7% and 3-year DFS was 74.1%.
For the definition of poor response, three of the papers [13, 14, 29] showing a statistical significance used a similar definition to each other, two [16, 31] used different definitions but were similar to each other and one study was different in its definition of poor response [26] . Using the definition given by Avallone et al [13] and comparing it to the other studies with similar definitions [14, 18, [28] [29] [30] , the reported DFS for poor response at 2 years was 60.3% to 68.9%, at 3 years was 72.6%, at 4 years was 47%, and at 5 years was 56%. Using the definition given by Suárez et al [31] and comparing it with the other studies with similar definitions [15, 16] , the reported DFS for poor response at 2 years was 83.6%, at 3 years was 73.8%, and at 5 years was 61.7% to 68.1%. Lim et al [26] reports a 5-year DFS of 63.6%. From these results it may be appropriate to use Mandard 1 to 2, 1 to 3 or 2 to 3 or Dworak 3 to 4, 2 to 4 or 2 to 3 for defining good response and Mandard 4 to 5, 3 to 5 or Dworak 0 to 1, 0 to 2 or Bujko 3 to define poor response.
Studies differentiating between good and poor response for OS
Nine reports [16, 26, 28, 29, 32] compared good and poor response in relation to OS ( Figure 5 ). Of these, all but one [29] showed OS was non-significantly worse in poor responders. Six reports from four papers showed a significant difference [16, 28, 29, 32] . For the definition of good response, two of the papers [16, 32] showing a statistical significance used a similar definition to each other; two reports from one paper [32] used different definitions but were similar to each other, and a further two used similar definitions to each other but were different from the other papers [28, 29] . Using the definition given by Pucciarelli et al [28] and comparing it with the other studies with similar definitions [29] , the reported OS for good response at 2 years was 92.2%. Using the definition given by Lim et al [26] and comparing it with the other studies with similar definitions [16, 26, 32] , the reported OS for good response at 5 years was 77.4% to 88.2%.
For the definition of poor response, two of the papers [28, 29] showing a statistical significance used a similar definition to each other and a further two studies had similar definitions to each other [16, 32] .
Two reports from one study were different in their definitions of poor response [32] . Using the definition given by Pucciarelli et al [28] and comparing it with other reports with similar definitions [29] , the reported OS for poor response was 87.3% at 2 years. Using the definition given by Vallböhmer et al [32] and comparing it with the studies with similar definitions [26] , the reported OS for poor response was 71.3% at 5 years. Using the next definition given by Vallböhmer et al [32] and comparing it with studies with similar definitions [16] , the reported OS for poor response was 60.7% to 69.1% at 5 years. From these results it may be appropriate to use Mandard 
Consensus histopathological definition of good and poor response
These results show that across the outcomes of LR, DR, DFS and OS, Mandard 1 to 2 and Dworak 3 to 4 could be used for defining good response and Mandard 3 to 5 and Dworak 0 to 2 for poor response.
MRI method of classifying regression
There was one mrTRG system using a 5-point scale [52] ( Table 8) . Lower mrTRG refers to greater regression and the system also divides the categories into type of response (complete, good, moderate, slight and none).
There were five papers on five studies reporting on poor response [5] [6] [7] 52, 53] . Characteristics of these studies can be seen in Table 9 . Overall, the reported proportion of poor responders after neo-adjuvant CRT was 38.6% (95%CI: 34.5%-42.8%) and there was only moderate heterogeneity that was still significant (Q = 10.7, df = 4, I 2 = 63, p = 0.03) ( Figure 6 ).
Definition of poor response as defined by MRI
Two studies [5] [6] [7] stated that mrTRG was based on the Dworak scale, but the hierarchy actually follows that of the Mandard scale (Table 10 ). Three studies stated that it was based on the Mandard scale [52, 53] . Poor response was defined as mrTRG 4 and mrTRG 5 by all of the papers. LR for poor responders at 5 years ranged from 4% to 29% [6, 52] . Five year DR was 9% [52] . From our centres, unpublished data for 3-year DFS was 52% [53] and 5-year DFS was 31% to 68% [6, 53] . OS at 3 years from this centre was 74% [53] and at 5 years was 27% to 68% [6, 53] .
Outcomes of good response defined by MRI TRG scales
LR rates for good responders at 5 years ranged from 1% to 14% [6, 52] . Five-year DR was 3% [52] and DFS was 64% to 83% [6, 53] . OS at 5 years was 72% to 90% [6, 53] ( Table 11 ).
Considerations and comparison between good and poor responders
mrTRG is a relatively new scale and the studies reporting it are from one centre; hence, consistency would be expected. Good responders were defined as mrTRG 1 to 3 or 1 to 2 and poor responders were defined as mrTRG 4 to 5 ( Table 12) .
Studies differentiating between good and poor responders for LR, DR, DFS and OS
There are three articles with available data comparing outcomes for good and poor responders (Table 11 ). In Although there was a range of survival outcomes, the overall rates for survival are lower in poor responders, distinguishing them clearly from the survival figures and rates of those with good response.
Consensus mrTRG definition of good and poor response
From these results, good response may be defined as mrTRG 1 to 3 or 1 to 2 (with mrTRG3 as a separate, independent group) and poor responders as mrTRG 4 to 5. This consistency of results, therefore, indicates the secondary hypothesis is likely to be true.
Publication bias for prevalence
Publication bias for prevalence from histology was initially assessed using a funnel plot (Figure 7 ). There appeared to be some asymmetry on the plot and so Eggers test was used. There was statistically significant asymmetry seen (Intercept: -4.30, SE: 2.23, 95%CI:-8.90-0.31, t = 1.93, p = 0.07), indicating there is unlikely to be significant publication bias.
Funding
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DISCUSSION
The aim of this review was to investigate the range and method of how poor response to neo-adjuvant therapy for rectal cancer is defined in order to see which scale best distinguishes between the two groups in relation to outcomes.
Main findings
In summary, this paper has shown that across the outcomes of LR, DR, DFS and OS, Mandard 1, 2 and Dworak 3, 4 could be used for defining good response and Mandard 3, 4, 5 and Dworak 0, 1, 2 for defining poor response. There are other definitions shown above which may also differentiate good and poor response. The analysis has shown differences in the reliability of these scales in consistently identifying good and poor responders.
Summary and appraisal of evidence
Our results have shown that there are three major challenges when it comes to the standardization of tumour regression for rectal cancer. The first is the vast choice of regression scales available to histopathologists. The second is that studies use these varied scales to define poor response without consistency. The third is that there are marked differences between the scales. Therefore, trying to merge these systems into one, universally acceptable 
Adjuvant therapy
Shihab et al [52] 2011 APR/AR Y Patel et al [7] and
Siddiqui et al [8] 2011 and 2012 APR/AR Y Patel et al [6] 2012 APR/AR Y T1/2/3/4, N0/1/2 Y Yu [53] 2014 (unpublished data from our centre)
Capecitabine, oxaliplatin ± cetuximab 50.4-54 Y T2/3/4 Y Yu [53] 2014 (unpublished data from our centre)
Capecitabine, oxaliplatin ± cetuximab 
DFS (%) OS (%)
Shihab et al [52] 2011 MRI TRG (based on Mandard)
Yes TRG 4,5 37 17 4 9
Patel et al [5, 7] 2012 MRI TRG (based on Dworak)
Yes TRG 4,5 69 22
Patel et al [6] and
Patel et al [7] 2011 
Yes TRG 1,2,3 37 20 1 3
Patel et al [6] 2012 MRI TRG (based on Dworak)
Yes TRG 1,2,3 69 47
Patel et al [5] and Patel et al [7] 2011 scale becomes unrealistic. Furthermore, studies have shown that inter-observer agreement amongst histopathologists using the existing scales is low [54] . The scales themselves do not advise on whether histopathologists should use a single worst slide for assessment or a composite assessment and adds to the challenge of defining good and poor response. This was highlighted by a study which showed poor inter-observer agreement between histopathologists assessing regression using different regression scales [54] . Some of the scales use qualitative estimates [25, 39, 46] for levels of fibrosis, but these overlap with regression grades in alternative scales given in other studies [35, 43] . Even by trying to examine the correlation between two systems, two grades may be grouped into one grade on a different scale.
Both MRI and histopathological grading systems are open for misinterpretation if standard methods of preparation and interpretation are not employed; there has been a focused attempt to do this in relation to histopathological assessment [54, 55] and mrTRG is a novel scale requiring appropriate training to ensure consistency when utilised in other centres. Differences in the definitions of poor response are highlighted by the number of poor responders identified in each of the studies (Figures 1 and 6 ). This review concentrated on studies using specific terms stating what they believed to be poor response; however, there were studies that divided TRG into two groups but did not specifically state them as good and poor responders; their results are consistent with the range that is reported in this paper but differ in that they show a good correlation to outcomes for their presumed good and poor responders [56] . In relation to the original definitions, one study showed that poor responders could be either those with predominant fibrosis or patients with tumour outgrowing fibrosis [31] compared with other studies using the same Mandard scale which only defined poor responders as those with tumour outgrowing fibrosis [22] . This is then compounded by the fact that more than one grade on other scales could be combined together on an alternative system.
Importance and implications for practice
Historically, the histopathological TRG systems were developed without validation of the grading in relation to outcomes, and evolution of these scales has occurred with the presence of long-term prognostic information. Histopathological TRG is also dependent on thorough pathological sampling and comparisons are not made to the pre-treatment biopsy; therefore, high stromal content tumours are often given a better regression grade, even though the high stroma may not be due to regression. mrTRG may be one way to respond to this, as it compares and examines the whole tumour and because of the presence of onescale heterogeneity is reduced. mrTRG also better distinguishes between good and poor response in relation to survival. LR appears to be reported with a large range using both histopathological and mrTRG and may relate to surgical factors being the most important issue in relation to this outcome.
Implications for research and further studies
Recent data from our centre would suggest that mrTRG3, whilst traditionally considered a good response, behaves more like the poor responder group [57] and could be considered as a separate group [58] . In summary, this paper has shown that across the outcomes of LR, DR, DFS and OS, Mandard 1 to 2 and Dworak 3 to 4 could be used for defining good [52] 2011
Better in GR No Better in GR Yes Good responders have better, statistically significant outcomes for DR but have better, non significant LR Patel et al [5] and Patel et al [7] 2011 and 2012
Better in GR No Better in GR Yes Better in GR Yes Good responders have better, statistically significant outcomes for DFS and OS but have better, non significant outcomes for LR Yu [53] 2014
Better in GR Yes Better in GR response and Mandard 3 to 5 and Dworak 0 to 2 for poor response. These definitions may help in achieving consensus in histopathological reporting. However, these definitions do not always produce a significant difference in the outcomes from the different studies utilizing these definitions. Furthermore, there are other definitions shown above which may also differentiate good and poor response. This casts doubt on the reliability of these scales in consistently identifying good and poor responders. A preoperative grading system, such as mrTRG, may be useful to appropriately differentiate good and poor response, thus guiding management decisions, and images attained could effectively be attained by high resolution MRI imaging. A range of histopathological TRG scales is used in clinical studies. Good and poor response are heterogeneously described, even when using the same histopathological regression scales. Across the outcomes of LR, DR, DFS and OS, Mandard 1 to 2 and Dworak 3 to 4 could be used for defining good response and Mandard 3 to 5 and Dworak 0 to 2 for poor response. These definitions may help in achieving consensus in histopathological reporting. Preoperative mrTRG is similarly able to differentiate between good and poor response based on outcomes.
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Background
Clinical studies use a number of different tumour regression grade (pTRG) scales to classify the degree of tumour response to neo-adjuvant chemoradiotherapy (CRT). This often results in confusion as to whether a good or poor response has been achieved, with subsequent uncertainty regarding treatment and prognostic implications. This problem was highlighted by studies that stress the importance of a universally accepted standard. There has been no review of the reported pTRG scales to date. It is necessary to highlight the heterogeneity in these scales, consolidate the current definitions with the purpose of converging towards a set of consensus definitions. This article investigates all the pathology tumour regression scales used to define good and poor response after neo-adjuvant chemotherapy for rectal cancer, to establish the true prevalence of poor responders and to identify the best scales to use in relation to outcomes.
Research frontiers
A newer method of assessing tumour regression relies on MRI (mrTRG), which has been validated as a prognostic tool. This may supercede pTRG, as it has the advantage of assessing tumour response before surgery. Potential enabling response-orientated tailored treatment, including alteration of the surgical planes, additional use of chemotherapy or deferral of surgery.
